French biotech InnoSkel says that close collaboration with the authorities and accelerated patient access were the key reasons why it decided to apply for an “innovation passport” under the UK’s Innovative Licensing and Access Pathway (ILAP). The passport was awarded this week to INS-101, a first-in-class gene therapy intended to treat the rare bone disorder, spondyloepiphyseal dysplasia congenita (SEDc).
SEDc has a prevalence of about 1 in 50,000. It is a genetic type II collagen disorder resulting from mutations...








